Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer

被引：0
|
作者：
Fernandez Madrigal, Laura
Garcia Samblas, Victoria
Amor Urbano, Maria
Inoriza, Angel
机构：
[1] Hosp Juan Ramon Jimenez, Huelva, Spain
[2] Hosp Juan Ramon Jimenez, Oncol Med, Huelva, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21153
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
    Hizal, Mutlu
    Bilgin, Burak
    Paksoy, Nail
    Kilickap, Saadettin
    Atci, Muhammed Mustafa
    Kahraman, Seda
    Keskinkilic, Merve
    Bilgetekin, Irem
    Ayhan, Murat
    Tural, Deniz
    Eren, Onder
    Akkoc Mustafayev, Fatma Nihan
    Yaman, Sebnem
    Tatli, Ali Murat
    Bayram, Ertugrul
    Kutlu, Yasin
    Erturk, Ismail
    Ozcan, Erkan
    Gulmez, Ahmet
    Korkmaz, Mustafa
    Akagunduz, Baran
    Erdem, Dilek
    Telli, Tugba Akin
    Aksoy, Asude
    Uskent, Necdet
    Iriagac, Yakup
    Baytemur, Naziyet Kose
    Aydin, Dincer
    Sakalar, Teoman
    Arak, Haci
    Selcukbiricik, Fatih
    Ergun, Yakup
    Korkmaz, Taner
    Ak, Naziye
    Unal, Caglar
    Akdeniz, Nadiye
    Ozgun, Mehmet Alpaslan
    Oksuzoglu, Berna
    Yalcin, Bulent
    Oztop, Ilhan
    Algin, Efnan
    Sakin, Abdullah
    Aydiner, Adnan
    Yumuk, Perran Fulden
    Nahit Sendur, Mehmet Ali
    FUTURE ONCOLOGY, 2022, 18 (23) : 2573 - 2582
  • [42] Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
    Watanabe, Satoshi
    Sakai, Kazuko
    Matsumoto, Naoya
    Koshio, Jun
    Ishida, Akira
    Abe, Tetsuya
    Ishikawa, Daisuke
    Tanaka, Tomohiro
    Aoki, Ami
    Kajiwara, Tomosue
    Koyama, Kenichi
    Miura, Satoru
    Goto, Yuka
    Sekiya, Tomoki
    Suzuki, Ryo
    Kushiro, Kohei
    Fujisaki, Toshiya
    Yanagimura, Naohiro
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Saida, Yu
    Yoshizawa, Hirohisa
    Nishio, Kazuto
    Kikuchi, Toshiaki
    CANCERS, 2023, 15 (01)
  • [43] COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Guler, B.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [44] Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study
    Solomon, Benjamin J.
    Bauer, Todd M.
    Ou, Sai-Hong Ignatius
    Liu, Geoffrey
    Hayashi, Hidetoshi
    Bearz, Alessandra
    Penkov, Konstantin
    Wu, Yi-Long
    Arrieta, Oscar
    Jassem, Jacek
    Calella, Anna M.
    Peltz, Gerson
    Polli, Anna
    Thurm, Holger
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3593 - +
  • [45] The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
    Srinivasamaharaj, Srividya
    Salame, Bilal Khameze
    Rios-Perez, Jorge
    Kloecker, Goetz
    Perez, Cesar A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1227 - 1233
  • [46] Acquired MET-Aberrance Is a Mechanism of Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer
    Deng, Q.
    Kang, J.
    Wang, H.
    Yang, J.
    Yan, H.
    Wang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S652 - S652
  • [47] Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Lin, Yen-Ting
    Wang, Yu-Fen
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    Wu, Shang-Gin
    Shih, Jin-Yuan
    Yang, Pan-Chyr
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1720 - 1725
  • [48] Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases
    Lei, Yuan-Yuan
    Yang, Jin-Ji
    Zhong, Wen-Zhao
    Chen, Hua-Jun
    Yan, Hong-Hong
    Han, Jie-Fei
    Yang, Lu-Lu
    Wu, Yi-Long
    JOURNAL OF THORACIC DISEASE, 2015, 7 (07) : 1181 - 1188
  • [49] Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
    Camidge, D. Ross
    Dziadziuszko, Rafal
    Peters, Solange
    Mok, Tony
    Noe, Johannes
    Nowicka, Malgorzata
    Gadgeel, Shirish M.
    Cheema, Parneet
    Pavlakis, Nick
    de Marinis, Filippo
    Cho, Byoung Chul
    Zhang, Li
    Moro-Sibilot, Denis
    Liu, Ting
    Bordogna, Walter
    Balas, Bogdana
    Mueller, Barbara
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : 1233 - 1243
  • [50] A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Jin, Y.
    Hu, X.
    Chen, M.
    Chen, Y.
    Shi, X.
    Yu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1952 - S1952
12345